MedTrace Logo

Tyrosine Kinase Inhibitor Withdrawal Syndrome in CML Patients: Observatory Trial Studying the Biological Factors.

NCT03996096 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2024-02-14

No results posted yet for this study

Summary

Patients who suffer from chronic myeloid leukemia are treated by tyrosin kinase inhibitors (TKI) saying imatinib, nilotinib, dasatinib, bosutinib and ponatinib. These drugs are highly efficient with excellent response allowing some patients to definitely stop their cancer treatment. However, in 30% of cases, when the treatment is stopped, pains could arise in shoulders, hips, joints… These symptoms occurring after the withdrawal of a drug are odd and biologically unexplained so far. This study seeks to discover the biological factors behind these symptoms called 'TKI withdrawal syndrome' by the scientific community.

Conditions

  • Chronic Myeloid Leukemia
  • Tyrosine Kinase Inhibitor
  • Withdrawal Syndrome

Sponsors & Collaborators

  • University Hospital, Caen

    lead OTHER

Principal Investigators

  • Hyacinthe JOHNSON-ANSAH, Dr · UNIVERSITY HOSPITAL of CAEN

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-04-23
Primary Completion
2023-03-16
Completion
2023-03-16

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03996096 on ClinicalTrials.gov